Tiotropium Bromide/Olodaterol (Stiolto Respimat): Once-Daily Combination Therapy for the Maintenance of COPD

Tiotropium bromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPD.

Saved in:
Bibliographic Details
Published inP&T (Lawrenceville, N.J.) Vol. 41; no. 2; pp. 97 - 102
Main Authors Mosley, 2nd, Juan F, Smith, Lillian L, Dutton, Brittany N
Format Journal Article
LanguageEnglish
Published United States MediMedia USA, Inc 01.02.2016
Subjects
Departments
Stiolto Respimat
beta2 agonist
tiotropium bromide
anti-cholinergic
COPD
olodaterol
Online AccessGet full text

Cover

More Information
Summary:Tiotropium bromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Disclosure: The authors report no commercial or financial interests in regard to this article.
Dr. Mosley and Dr. Smith are Assistant Professors of Pharmacy Practice at the Florida Agricultural and Mechanical University, College of Pharmacy and Pharmaceutical Sciences, in Crestview, Florida. Brittany Dutton is a Doctor of Pharmacy candidate at that institution. Drug Forecast is a regular column coordinated by Alan Caspi, PhD, PharmD, MBA, President of Caspi & Associates in New York, New York.
ISSN:1052-1372